Digital healthcare platform GoodRx has announced three senior leadership appointments, naming Raj Beri as the main operational offer, Mark Hull as product manager and Vina Leite as Director of Human Resources, according to a Monday (May 9) Press release.
The publicly traded company said in its statement that the leaders were added “to support the company’s scaling activities and accelerate innovation to deliver more affordable and convenient healthcare to consumers.” Across the country”.
According to the statement, Beri is GoodRx’s first chief operating officer and comes from Uber, where he was vice president of grocery and new verticals. He oversaw last mile and non-restaurant delivery operations globally.
“I’m passionate about working on bold issues in industries ripe for disruption, and GoodRx is at the center of that disruption in healthcare,” Beri said.
Hull, GoodRx’s first product manager, comes from Meta and LinkedIn, where he was senior product manager.
“Mark will draw on his more than 25 years of experience in the product management industry to make GoodRx more accessible, convenient and useful for consumers, while helping to expand opportunities with partners,” said Mark. communicated.
Additionally, Leite is GoodRx’s first Chief Human Resources Officer, bringing decades of experience in global human resources and talent management.
GoodRx also announced the hiring of Scott Paul as senior vice president of consumer health and innovation, who previously worked at MedImpact and Apex Affinity. The announcement also said that Andrew Slutsky “will move into a new role within the company, driving new initiatives as Senior Vice President of Marketing Strategy and Innovation.”
GoodRx, which claims in its marketing materials that it has helped consumers save more than $35 billion since 2011, recently topped the PYMNTS provider rankings for prescription apps.
See also: GoodRX pays $150 million for vitaCare health platform
On March 1, GoodRx announced the acquisition of vitaCare Prescription Services from TherapeuticsMD for $150 million. GoodRx also said it would pay an additional $7 million, depending on vitaCare’s financial performance through next year.
GoodRx Holdings, Inc. began trading the 2022 calendar on the Nasdaq market at $32.45 per share. As of 3:30 p.m. Eastern Daylight Time on May 9, shares were trading at $10.76 a share, down 67%.